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Effect of Pollen-Specific Sublingual Immunotherapy
on Oral Allergy Syndrome
An Observational Study
Karl-Christian Bergmann, MD,* Hendrik Wolf, PhD,** and Jo¨rg Schnitker, PhDþ
Background: Oral allergy syndrome (OAS) triggered by fruit and
vegetables often occurs in patients with pollen-induced rhinocon-
junctivitis because of cross-reactive epitopes in pollen and associated
foods. This open observational study examined the effect of pollen-
specific sublingual immunotherapy ([SLIT] B. U. Pangramin or
SLITone involving birch/alder/hazel, grasses/rye, and/or mugwort)
on OAS triggered by several foods in patients treated in standard
practice. Very few studies have examined SLIT use in this situation.
Methods: Patients (n = 102) had pollen-induced rhinoconjunctivitis
and OAS and were followed for up to 12 months. Baseline OAS
(triggers, symptoms, and symptom severity) was assessed by
questionnaire and patient history. Change in OAS was assessed
using oral challenge test with 1 or 2 dominant food triggers (and
compared with the sum score calculated from the OAS questionnaire
at baseline) and clinician ratings of change. Pollen-induced
rhinoconjunctivitis symptoms and medication use were also
measured.
Results: In the oral challenge test, 77.0% of patients were considered
responders (decrease in sum score of Q50%; no difference in patients
receiving B. U. Pangramin or SLITone). At baseline, investigators
rated OAS severity as at least moderate in 94.9% of patients
compared with 36.9% after 12 months of treatment. After 12 months,
OAS was rated as much or very much improved in 72.9% of patients.
Sublingual immunotherapy significantly reduced rhinoconjunctivitis
symptoms and medication use. Only 10% of patients experienced
adverse drug reactions.
Conclusions: This study supplements the sparse literature on this
topic and suggests that pollen-specific SLIT can reduce OAS
triggered by pollen-associated foods in patients with pollen-induced
rhinoconjunctivitis.
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(WAO Journal 2008;79Y84)
Up to 70% of patients with pollen allergy also experienceoral reactions to food (oral allergy syndrome [OAS]),
typically fruit and vegetables.1Y3 Although most cases of OAS
result in mild symptoms (itching of lips, mouth, and throat),
more severe (lip and tongue swelling, angioedema of the
pharyngeal mucosa) and even life-threatening (anaphylactic)
symptoms can occur.4,5
Specific immunotherapy with pollen allergens may have
a beneficial effect on pollen-associated food allergy triggering
OAS because of cross-reactive epitopes present in pollen and
associated foods.6,7 However, studies investigating the effect
of subcutaneous pollen-specific immunotherapy on OAS
report mixed results: some authors describe a reduction in
OAS, whereas others have found no or only limited benefits
from immunotherapy.8Y14
Pollen-specific sublingual immunotherapy (SLIT) is an
alternative way of administering specific immunotherapy,
which has been shown to be effective in reducing pollen-
induced allergic rhinitis in several studies.15Y19 Sublingual
immunotherapy is applied directly to the oral mucosa, the site
of the OAS reaction, and may therefore offer additional
benefits over subcutaneous immunotherapy. This proposal is
consistent with general clinical experience that initial mild
adverse reactions to SLIT, such as oral itching and mucosal
swelling, typically disappear during continued application of
SLIT.20
To our knowledge, only 2 studies have investigated
the effects of pollen-specific SLIT on OAS triggered by
pollen-associated foods.21,22 Hansen et al21 compared
SLIT and subcutaneous immunotherapy with placebo in
birch-allergic patients with OAS triggered by apple. No
effect of immunotherapy on OAS was found, as assessed
by a questionnaire and an open oral challenge test, but the
number of patients receiving SLIT was small (n = 11).
Kinaciyan et al22 also failed to find an effect of birch-pollen
SLIT on OAS to apple. Recently, however, Enrique et al23
showed that SLIT was effective in reducing food allergies:
hazelnut-intolerant patients (n = 12) demonstrated significant
increases in tolerance to hazelnut after SLIT with hazelnut
extract as assessed by a double-blind placebo-controlled
food challenge in a randomized, double-blind, placebo-
controlled study.
This open observational study further explores the
inf luence of SLIT on OAS, thereby adding to the very limited
literature in this area. The effects of immunotherapy with
various pollen allergens in patients with pollen-induced
rhinoconjunctivitis and pollen-associated OAS were recorded
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by practicing allergists during routine application of commer-
cially available SLIT products.
METHODS
Patients
Patients had pollen-induced allergic rhinoconjunctivitis
and concomitant OAS and did not have known contra-
indications to specific immunotherapy. Data were recorded
between September 2002 and June 2005 during routine SLIT
treatment by practicing allergists located throughout Germany.
Study Design
The study was open, noninterventional, and observa-
tional. Sublingual immunotherapy was administered by
patients at home. Before SLIT initiation, demographic data,
the history, and diagnostic measures with respect to pollen
allergy and OAS were recorded. In an OAS questionnaire
completed by the patients at that time, patients were asked to
specify all foods that triggered their OAS symptoms, to name
1 or 2 foods provoking the most severe symptoms, to record
the severity of symptoms (none/mild/moderate/severe) when
last exposed to these foods, and to record the time of OAS
onset after food intake. A weighted sum score was calculated
from the 18 different symptoms assessed in this questionnaire
(Table 1). Additional assessments (OAS severity, change in
OAS status, response to foods) were performed during patient
visits at the end of the initial treatment phase, and after 6 and
12 months of maintenance treatment (Table 2). The OAS
severity and change in OAS status were assessed by the
physician using the 7-point Clinical Global Impression Scales
(OAS severity: not ill/borderline case/mildly ill/moderately ill/
markedly ill/severely ill/among the most extremely ill; change
of OAS status: very much improved/much improved/only
minimally improved/unchanged/minimally worse/much
worse/very much worse). Response to foods was rated as:
food avoided/food tolerated without reaction/food better
tolerated/reaction to food unchanged/food tolerance deterio-
rated. An open oral challenge test with the 1 or 2 foods
identified as the most severe OAS triggers was scheduled after
6 and 12 months of maintenance therapy. The severity of
symptoms triggered by the food challenge were assessed using
a scale of none/mild/moderate/severe for 18 different
symptoms and evaluated as weighted sum score as used for
the OAS questionnaire (Table 1). Results from this test were
compared with the weighted sum scores calculated from the
OAS questionnaire at the beginning of SLIT.
Weighted sum score ¼ ~18
i¼1
weighti  symptomi
A rhinoconjunctivitis symptom score from 0 to 21 was
obtained by totaling scores for 3 eye symptoms (itching/tear
f low/and redness) and 4 nasal symptoms (obstruction/itching/
rhinorrhea/sneezing): each symptom was scored retrospec-
tively for the preceding pollen season on a scale of 0 to 3 (no/
mild/moderate/severe symptoms). Lung symptoms were
assessed for 4 items (chest tightness/wheezing/cough/dys-
pnea), and skin symptoms, for 2 items (pruritus/eczema).
Optionally, a nasal provocation test (NPT) was performed
according to the Position Paper of the German Society for
Allergology and Clinical Immunology about application of the
NPT on diseases of the upper airways.24
Patients were also asked about medication use (Yes/No
for a range of typical allergy medications) and whether
sleeping was impaired by their allergy symptoms. Rhinocon-
junctivitis symptoms were reassessed during the first pollen
season after starting SLIT, and the NPT was optionally
performed. At the end of the 12-month observation period, the
status of the patient in the first pollen season with SLIT
compared with the pretreatment season was assessed globally
by patient and physician (better/unchanged/worse/not asses-
sable). The doses applied and potential adverse reactions
throughout the study were recorded in patient diaries.
TABLE 1. The OAS Questionnaire and Weighted Sum Score
No. Symptom Weight
1 Itchy lips 1
2 Itchy tongue 1
3 Itchy oral mucosa 1
4 Burning tongue 1
5 Swelling of the lips 1
6 Swelling of the tongue 1
7 Swelling of the oral mucosa 1
8 Swelling of the larynx 1
9 Inflammation of the tongue 1
10 Inflammation of the oral mucosa 1
11 Eye symptoms 2
12 Nose symptoms 2




17 Gastrointestinal disorders 3
18 Collapse, shock 4
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test (1 or 2 times)
& &
Rhinoconjunctivitis symptoms &* &** &**
Rhinoconjunctivitis medication &* &** &**
Nasal provocation test & & &
SLIT, SLIT safety & & &
Patients’ diary & &
*Last pollen season.
**Once after f irst SLIT season.
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SLIT Preparations and Dosage
Sublingual immunotherapy was typically initiated with
B. U. Pangramin SLIT pollen allergens [grass mix/rye, tree
mix (hazel/alder/birch) and mugwort; ALK-SCHERAX
Arzneimittel GmbH, Wedel, Germany], although a few
patients started on SLITone (available from November 2003;
ALK-SCHERAX Arzneimittel GmbH). The recommended
treatment regimen for B. U. Pangramin SLIT involved an
initial 4-week updosing phase followed by maintenance
treatment involving 10 drops from a vial of strength 500
Specific Treatment Units Abello (STU)/mL 3 times a week.
For SLITone, the recommended regimen involved an initial
10-day updosing phase followed by a single daily maintenance
dose of 200 STU (0.2 mL of 1000 STU/mL concentration).
During the updosing phases, patients were advised to increase
the dose according to the dosage schedule only if the previous
dose had been applied and if the dose was well tolerated. If
adverse reactions occurred, patients were instructed to contact
their physician. For both products, patients were told to keep
the SLIT drops under the tongue for 2 to 3 minutes before
swallowing. During the study, some patients switched from B.
U. Pangramin SLIT to SLITone grass mix and rye or tree mix.
In these cases, treatment with SLITone was always started with
the initial 10-day updosing phase.
RESULTS
Patient Characteristics
Overall, 102 patients were treated with at least 1 dose
of SLIT (88 patients were treated with B. U. Pangramin SLIT,
11 were initially treated with B. U. Pangramin and then trans-
ferred to SLITone; 3 patients initiated SLIT with SLITone).
Seventy-seven patients were considered to have completed
the 12-month observation period. Reasons for not completing
the study were adverse events (n = 8), lack of compliance
(patients, n = 6; investigators, n = 3), improvement (n = 3),
lack of efficacy (n = 2), lack of compliance + lack of efficacy
(n = 1), termination by the patient (n = 1), and desire to start a
family (n = 1); data from 2 of these patients were, however,
included in some of the analyses. Of the 99 patients receiving
B. U. Pangramin SLIT, 87 achieved the maximum main-
tenance dose after 4 weeks (n = 75) or delayed after a longer
updosing phase (n =12). Three patients were lost to follow-up
at an unknown maintenance dose, 4 discontinued treatment
at a submaximum level because of allergic adverse reactions,
3 patients named allergic symptoms because of pollen
exposure as the reason for discontinuing updosing (no
subsequent continuation was documented), and in 2 patients,
a submaximum maintenance dose was chosen because of
other medical reasons. In total, the maximum B. U. Pangramin
SLIT dosage was reached in 87.9% of the patients.
Patient characteristics and OAS history at baseline are
shown in Table 3. Patients were most frequently sensitized to
birch/alder/hazel followed by grasses/rye and mugwort.
Accordingly, patients experienced OAS reactions predomi-
nantly to tree-associated foods: apple (81.8%) and hazelnut
(73.7%), and with lower frequency to carrot (27.3%). Patients
completing the OAS questionnaire named 175 dominant
triggers as causing the most marked symptoms. The most
commonly named dominant triggers in the questionnaire were
apple (33.1%, 58/175), hazelnut (22.3%, 39/175), carrot
(8.0%, 14/175), peach (3.4%, 6/175), and celery (3.4%, 6/
175). Symptoms to these dominant triggers mostly occurred
within 5 minutes of eating the food, and 25.4% of symptoms
were considered severe. Only 7.1% of reactions required
immediate medical attention. Most patients (79.4%) received
SLIT with tree allergens, 37.3% received SLIT with grasses
and rye, and 5.9% received SLIT with mugwort.
Effect of SLIT With Pollen Allergens on OAS
During the course of the study, patients frequently
avoided foods that provoked OAS reactions. The rate of food
avoidance for dominant OAS triggers decreased from 65.5%
after 4 weeks’ treatment to 40.0% after 12 months (Fig. 1); 71
(40.6%) of the 175 named dominant triggers of OAS were
avoided during the study. After 4 weeks’ treatment, 24 (40.7%
of patient cases) of the 59 food types ingested were tolerated
without reaction or better than previously. After 12 months,
this value increased to 86.4% (70/81).
TABLE 3. Patient Characteristics and OAS History at Baseline
Patients Treated With SLIT n = 102
Median age, yrs (range) 34.5 (6Y64)
Children G14 yrs, % 13.7
Male/female, % 33.3 / 66.7
Median duration of rhinoconjunctivitis, yrs (range) 8.0 (1Y37)
Patients with pollen-induced airway
symptoms, %
62.7
Patients with pollen-induced skin
symptoms, %
23.5
Positive skin prick test to: n (%)
Grasses and rye 63 (67.7)
Birch, alder, hazel 93 (93.9)
Beech, oak, ash 35 (50.7)
Mugwort 26 (34.2)
Other pollen 5 (12.8)
House dust mites 27 (34.2)
Animal dander 22 (31.0)
SLIT treatment with (includes multiple entries): n (%)
Tree mix (birch, alder, hazel) 81 (79.4)
Grasses and rye 38 (37.3)
Mugwort 6 (5.9)
OAS history
Patients evaluable n = 99





Predominant symptoms OAS reactions with
this symptom, %
Itchy lips, tongue, and/or oral mucosa 83.4
Swelling of lips, tongue, oral mucosa, and/or larynx 74.3
Burning of tongue 40.0
Eye symptoms 34.9
Nose symptoms 32.6
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In the oral challenge test, weighted sum score decreased
by a mean of 64.3 relative to the reactions recorded in the
OAS questionnaire before SLIT initiation. Defining a
response as a decrease in sum score of 50% or more, 77.0%
of patients were responders in the oral challenge test
(confidence interval, 64.5Y86.9, P G 0.0001, n = 61), and
most of these patients experienced a reduction in sum score of
more than 75% (Fig. 2). There was no significant difference in
response in patients receiving B. U. Pangramin SLIT or
SLITone. In patients with apple intolerance (the most common
food trigger) who underwent an oral challenge test with this
food, 89.2% (33/37) responded to SLIT (decrease in sum score
of at least 50%). The respective percentage for hazelnut-
intolerant patients was 69.6% (16/23).
Investigators reported a decrease in OAS severity after
SLIT; at baseline, 94.9% of patients were rated as at least
moderately ill compared with 36.9% at month 12. Further-
more, after 6 months of SLIT treatment, investigators rated
OAS as much or very much improved in 53.9% (48/89) of
patients. This percentage increased to 72.9% (54/74) in
patients completing 12 months of therapy. In all patients
receiving treatment (regardless of how long), 65.7% (65/99)
were rated by the investigators as much or very much
improved.
Effect of SLIT on Pollen-Induced
Rhinoconjunctivitis
Sublingual immunotherapy treatment markedly decreased
rhinoconjunctivitis symptoms during the pollen season in the
completer population (Fig. 3). The mean symptom severity
score for eye symptoms decreased by 58.4%, nose symptoms by
FIGURE 1. Exposure to, and tolerability of, dominant OAS triggers.
FIGURE 2. The OAS challenge test at 6 and 12 months compared with the results of the OAS questionnaire at baseline (weighted
sum score). The ﬁgure presents individually the last ﬁndings for each included patient (n = 61; 8 tests at 6 months, 53 tests at
12 months). CI indicates conﬁdence interval.
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54.2%, bronchial symptoms by 79.2%, and skin symptoms by
85.9%. Insomnia improved in 60.0% of cases.
After SLIT, symptomatic medication was reduced or no
longer required in 92.1% (n = 70) of patients who were using
medication at baseline (n = 76). Forty-nine patients completed
an NPT before and after SLIT; 34.7% of them had a positive
test before and a negative test after SLIT. Of patients and
investigators, 84.2% rated well-being during the pollen season
as improved after SLIT relative to the last pollen season before
immunotherapy. There was no difference in well-being
assessment between B. U. Pangramin and SLITone.
Tolerability of SLIT
Of the 99 patients who received at least 1 dose of B. U.
Pangramin SLIT, 10 (10.1%) had a total of 14 adverse drug
reactions [asthma attack (n = 2), nausea (n = 2), retching,
neurodermatitis, angina, diarrhea, OAS worsening, anaphy-
lactic event of undetermined origin, prickling of the tongue
(n = 2), numbness of the tongue, burning of the tongue].
No adverse drug reactions were recorded with SLITone. Only
1 patient discontinued SLIT because of deterioration of
OAS after the initial therapy. In total, 8 of the adverse drug
reactions resulted in treatment discontinuation. These included
asthma (n = 2) and single cases of OAS worsening, severe
angina, neurodermatitis, nausea, anaphylactic event of unde-
termined origin (not temporally related to SLIT), and prickling
tongue. Overall, 94.7% of patients and 95.7% of physicians
rated the tolerability of initial SLIT as very good (patients,
76.8%; physicians, 77.7%) or good (patients, 17.9%; physi-
cians, 18.1%). Similar results were reported after 6 and 12
months of maintenance therapy (patients, 93.9%; physicians,
96.3%; and patients, 94.7%; physicians 96.1%, respectively).
DISCUSSION
In this open observational study, we found that patients
treated with pollen-specific SLIT during routine clinical
treatment showed improvements in OAS triggered by various
pollen-associated food allergens (when these foods were
ingested naturally or during an oral challenge test) and in
pollen-induced rhinoconjunctivitis. Furthermore, the improve-
ment increased as treatment continued for up to 12 months.
Physicians rated OAS as much or very much improved in
nearly 75% of patients after 12 months of treatment, and 77%
of patients had a favorable response in the open oral challenge
test. The symptoms of allergic rhinoconjunctivitis were also
improved during the first pollen season after SLIT treatment.
Although our study was not controlled, OAS does not
normally improve without treatment.2,8,11 For example, in a
study of specific injection immunotherapy in birch pollenY
sensitive patients with apple-induced OAS, none of the
20 control patients reported a reduction in symptoms during
a 12- to 48-month follow-up period8; in contrast, 84% of
immunotherapy-treated patients reported complete disappear-
ance or significant improvement in symptoms. It is our
opinion that an improvement in OAS symptoms to the extent
reported in this study would not normally be expected without
treatment. Furthermore, annual variations in pollen count are
unlikely to account for our findings because patients were
recruited and treated over several years and were allergic to
different pollens.
To our knowledge, only 2 other studies21,22 have
investigated the effect of pollen-specific SLIT in patients
with concomitant OAS. In both studies, no effect of birch-
allergen SLIT or subcutaneous immunotherapy on OAS
triggered by apple was reported relative to placebo, but the
number of patients treated with SLIT and assessed by food
challenge was low (11 patients21 and 9 patients22). The
recently published study by Kinaciyan22 classified patients
allergic to birch who had been treated with SLIT as responders
and nonresponders according to the outcome in an NPT.
The 9 patients who had a positive response in the NPT were
tested by double-blind placebo-controlled food challenge and
oral food challenge with apple. No significant differences
between the food challenges at baseline and after 1 year of
SLIT were observed. The authors speculate based on the
results of T-cell proliferation experiments that an exclusively
food-specific T-cell response to Mal d 1 (a protein with an
amino acid sequence that is 64% similar to the major birch
pollen allergen, Bet v 1) may exist that can only be altered if
OAS-related food allergens are contained in the vaccine for
SLIT. Consistent with this argument, another study showed
that patients with OAS and food allergy to hazelnut can be
successfully treated with SLIT using a hazelnut extract
containing the most relevant allergens triggering OAS and
food allergy.23
Nevertheless, our observational study involving a much
larger sample of 102 patients with pollen-induced allergy and
concomitant OAS suggests that patients treated routinely with
pollen allergen SLIT can report positive effects of SLIT on
OAS. This is consistent with several studies that have shown
benefits of subcutaneous pollen-specific immunotherapy on
concurrent OAS using open2,8,13,14 or blinded,11 and con-
trolled2,8,11,14 or uncontrolled13 designs. Furthermore, SLIT
may have the potential to inf luence OAS more strongly than
subcutaneous treatment because of the application of allergens
directly to the oral mucosa and the subsequent induction of
oral tolerance. To explore the effect of SLIT on OAS further,
controlled blinded clinical trials should be undertaken.
Nevertheless, this study extends the available literature in
FIGURE 3. Course of rhinoconjunctivitis symptom scores.
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this field, particularly by studying a wider variety of patients,
treatments, and OAS triggers, more indicative of the real-life
clinical setting.
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